Use of preoperative desmopressin in preventing bleeding in patients treated with selective serotonin reuptake inhibitors (SSRIs)

Submission date	Recruitment status	Prospectively registered
20/12/2005	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
20/12/2005	Completed	Results
Last Edited	Condition category	Individual participant data
02/09/2008	Surgery	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr S.C. Marczinski

Contact details

Willy Brandtlaan 10 Ede Netherlands 6716 RP +31 (0)318 435546 Marczinskis@zgv.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

UMCU 04-298; NTR175

Study information

Scientific Title

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised, double-blinded, placebo controlled, parallel group trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Not Specified

Participant information sheet

Health condition(s) or problem(s) studied

Primary haemostasis disorder

Interventions

Pre-operative infusion placebo/desmopressin:

- 1. Less than 50 kg: 15 μg
- 2. 50 100 kg: 30 µg
- 3. Greater than 100 kg: 45 µg

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Desmopressin

Primary outcome measure

Pre- and post-operative blood loss.

Secondary outcome measures

- 1. Peri- and post-operative haemoglobin
- 2. Number of peri-operative blood transfusion
- 3. Peri-operative fluid infusion
- 4. Post-operative drainage

Overall study start date

01/01/2005

Completion date

01/06/2007

Eligibility

Key inclusion criteria

- 1. Patients aged over 18 who receive a serotonergic antidepressant (fluvoxamine, fluoxetine, paroxetine, sertraline, venlafaxine, clomipramine, citalopram) at least started two weeks before the surgery
- 2. Surgery: orthopedic, abdominal, breast

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Not Specified

Target number of participants

300. Patients have been recruited since 07/04/05.

Key exclusion criteria

- 1. No informed consent
- 2. Disorder in primary haemostasis
- 3. Hyponatraemia (sodium [serum] less than 130 mmol/l)
- 4. Laparoscopic surgery
- 5. Use of vitamin K antagonists, aspirin, iron supplements, methotrexate, heparin
- 6. Acute coronary syndrome (unstable angina and myocardial infarction)
- 7. Spinal anaesthesia during surgery

Date of first enrolment

01/01/2005

Date of final enrolment

Locations

Countries of recruitment

Netherlands

Study participating centre
Willy Brandtlaan 10
Ede
Netherlands
6716 RP

Sponsor information

Organisation

Hospital Gelderse Vallei (The Netherlands)

Sponsor details

P.O. Box 9025 Ede Netherlands 6710 HN

Sponsor type

Hospital/treatment centre

ROR

https://ror.org/03862t386

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Hospital Gelderse Vallei (The Netherlands)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration